SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Schedule 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 5)*

Aimmune Therapeutics, Inc.								
(Name of Issuer)								
Common Stock								
(Title of Class of Securities)								
00900T107								
(CUSIP Number)								
December 31, 2019								
(Date of Event Which Requires Filing of this Statement)								
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:								
□ Rule 13d-1(b)								
⊠ Rule 13d-1(c)								
□ Rule 13d-1(d)								
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.								
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).								
(Continued on following pages)								
Page 1 of 11								
Exhibit Index on Page 11								

CUSIP # 00900T107 Page 2 of 11

1	NAME OF REPORTING PERSONS Foresite Capital Fund II, L.P. ("FCF II")						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)					(b)	X
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0 shares.				
		6	SHARED VOTING POWER See response to row 5.				
		7	SOLE DISPOSITIVE POWER 0 shares.				
		8	SHARED DISPOSITIVE POWER See response to row 7.				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				0		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0%		
12	TYPE OF REPORTING PERSON			PN			

CUSIP # 00900T107 Page 3 of 11

1	NAME OF REPORTING PERSONS Foresite Capital Management II, LLC ("FCM II")						
2	CHECK THE APP	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					X
3	SEC USE ONLY	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0 shares.				
		6	SHARED VOTING POWER See response to row 5.				
		7	SOLE DISPOSITIVE POWER 0 shares.				
		8	SHARED DISPOSITIVE POWER See response to row 7.				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				0		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0%		
12	TYPE OF REPORTING PERSON				ОО		

CUSIP # 00900T107 Page 4 of 11

1	NAME OF REPORTING PERSONS Foresite Capital Fund III, L.P. ("FCF III")							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)					(b)	X	
3	SEC USE ONLY							
4	CITIZENSHIP OR Delaware	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0 shares.					
		6	SHARED VOTING POWER See response to row 5.					
		7	SOLE DISPOSITIVE POWER 0 shares.					
		8	SHARED DISPOSITIVE POWER See response to row 7.					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0%			
12	TYPE OF REPORTING PERSON				PN	•		

CUSIP # 00900T107 Page 5 of 11

1	NAME OF REPORTING PERSONS Foresite Capital Management III, LLC ("FCM III")						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)					(b)	X
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0 shares.				
		6	SHARED VOTING POWER See response to row 5.				
		7	SOLE DISPOSITIVE POWER 0 shares.				
		8	SHARED DISPOSITIVE POWER See response to row 7.				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				0		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0%		
12	TYPE OF REPORTING PERSON				00		

CUSIP # 00900T107 Page 6 of 11

1	NAME OF REPORTING PERSONS James Tananbaum ("Tananbaum")						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)					(b)	X
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0 shares.				
		6	SHARED VOTING POWER See response to row 5.				
		7	SOLE DISPOSITIVE POWER 0 shares.				
		8	SHARED DISPOSITIVE POWER See response to row 7.				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				0		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0%		
12	TYPE OF REPORTING PERSON				IN		

CUSIP # 00900T107 Page 7 of 11

ITEM 1(A). NAME OF ISSUER

Aimmune Therapeutics, Inc. (the "Issuer")

ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

8000 Marina Blvd., Suite 300 Brisbane, CA 94005

ITEM 2(A). NAME OF PERSONS FILING

This Schedule is filed by Foresite Capital Fund II, L.P., a Delaware limited partnership, Foresite Capital Management II, LLC, a Delaware limited liability company, Foresite Capital Fund III, L.P., a Delaware limited partnership, Foresite Capital Management III, LLC, a Delaware limited liability company and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons."

ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE

The address for each of the Reporting Persons is:

c/o Foresite Capital Management 600 Montgomery Street, Suite 4500 San Francisco, CA 94111

ITEM 2(C). <u>CITIZENSHIP</u>

See Row 4 of cover page for each Reporting Person.

ITEM 2(D). TITLE OF CLASS OF SECURITIES

Common Stock

ITEM 2(D) <u>CUSIP NUMBER</u>

00900T107

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS

<u>A:</u>

Not applicable.

ITEM 4. <u>OWNERSHIP</u>

The following information with respect to the ownership of the common stock of the Issuer by the persons filing this Statement is provided as of December 31, 2019:

CUSIP # 00900T107 Page 8 of 11

(a) Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b) <u>Percent of Class</u>:

See Row 11 of cover page for each Reporting Person.

- (c) <u>Number of shares as to which such person has:</u>
 - Sole power to vote or to direct the vote
 See Row 5 of cover page for each Reporting Person.
 - (ii) Shared power to vote or to direct the vote

See Row 6 of cover page for each Reporting Person.

- (iii) <u>Sole power to dispose or to direct the disposition of</u>
 - See Row 7 of cover page for each Reporting Person.
- (iv) Shared power to dispose or to direct the disposition ofSee Row 8 of cover page for each Reporting Person.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of 5 percent of the class of securities, check the following \boxtimes .

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not applicable

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8. <u>IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.</u>

Not applicable

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not applicable

ITEM 10. CERTIFICATION.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP # 00900T107 Page 9 of 11

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2020

FORESITE CAPITAL FUND II, L.P.

By: FORESITE CAPITAL MANAGEMENT II, LLC

Its: General Partner

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member

FORESITE CAPITAL MANAGEMENT II, LLC

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member

FORESITE CAPITAL FUND III, L.P.

By: FORESITE CAPITAL MANAGEMENT III, LLC

Its: General Partner

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member

FORESITE CAPITAL MANAGEMENT III, LLC

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member

JAMES TANANBAUM

By: /s/ James Tananbaum
Name: James Tananbaum

CUSIP # 00900T107 Page 10 of 11

EXHIBIT INDEX

Exhibit Found on Sequentially Numbered Page

Exhibit A: Agreement of Joint Filing

CUSIP # 00900T107 Page 11 of 11

EXHIBIT A

Agreement of Joint Filing

The Reporting Persons hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.